المؤلفون: Maddaloni, Ernesto, Cavallari, Ilaria, La Porta, Ylenia, Appetecchia, Alessandro, D'Onofrio, Luca, Grigioni, Francesco, Buzzetti, Raffaella, Holman, Rury R.

المصدر: Diabetes, Obesity and Metabolism ; volume 25, issue 5, page 1341-1350 ; ISSN 1462-8902 1463-1326

الوصف: Aim To determine whether the magnitude of the cardiorenal benefits of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) varies with baseline kidney function. Methods We searched randomized, placebo‐controlled trials testing the effects of SGLT2is on renal and cardiovascular outcomes. Efficacy outcomes, stratified by baseline estimated glomerular filtration rate (eGFR) categories, included renal disease progression, a composite heart failure (HF) outcome and mortality. Results Thirteen trials testing SGLT2is in 90 402 participants with available eGFR data were included. The risk of bias was judged as low for all trials. SGLT2is reduced the relative risks of renal disease progression by 27% to 57% and of HF outcomes by 13% to 32% across different eGFR categories, with an overall low heterogeneity. Meta‐regression analyses showed a significant direct relationship between baseline eGFR and the magnitude of SGLT2is’ renal protection ( P = .003). The greatest risk reduction was in participants with an eGFR of 90 ml/min/1.73m 2 or higher (HR 0.43, 95% CI: 0.32‐0.58) and the smallest was in those with an eGFR of less than 30 ml/min/1.73m 2 (HR 0.73, 95% CI: 0.62‐0.86, P < .001). Conversely, for HF, the greatest risk reduction was in those with an eGFR of less than 30 ml/min/1.73m 2 (HR 0.68, 95% CI: 0.48‐0.96) and the smallest was in those with an eGFR of 90 ml/min/1.73m 2 or higher (HR 0.87, 95% CI: 0.56‐1.34). Conclusions SGLT2is reduce the risk of renal and HF outcomes for all eGFR categories. The greatest benefits in terms of kidney protection may be achieved by early initiation of SGLT2is in people with preserved eGFR. The greatest risk reduction for HF outcomes is observed in people with lower eGFR values.

الإتاحة: https://doi.org/10.1111/dom.14986Test

المؤلفون: Crispino, Simone Pasquale, Segreti, Andrea, La Porta, Ylenia, Liporace, Paola, Carpenito, Myriam, Cammalleri, Valeria, Grigioni, Francesco

المصدر: Monaldi Archives for Chest Disease; 2024, Vol. 94 Issue 1, p4-8, 5p

مصطلحات موضوعية: PATENT foramen ovale, EXERCISE tests, PULMONARY hypertension, HEART failure, HEART failure patients

مستخلص: A 55-year-old male affected by heart failure with reduced ejection fraction and a history of a transient cerebrovascular accident was accepted to the Cardiology Department for worsening dyspnea. A cardiopulmonary exercise test was performed after therapy optimization to further evaluate exercise intolerance. A rapid increase in the minute ventilation/carbon dioxide production ratio, end-tidal oxygen pressure, and respiratory exchange ratio, with a concomitant decrease in end-tidal carbon dioxide pressure and oxygen saturation, were observed during the test. These findings indicate exercise-induced pulmonary hypertension leading to a right-to-left shunt. Subsequent echocardiography with a bubble test unveiled the presence of an unknown patent foramen ovale. It is, therefore, necessary to exclude a right-to-left shunt by cardiopulmonary exercise testing, particularly in patients predisposed to develop pulmonary hypertension during exercise. Indeed, this eventuality might potentially provoke severe cardiovascular embolisms. However, the patent foramen ovale closure in patients with heart failure with reduced ejection fraction is still debated because of its potential hemodynamic worsening. [ABSTRACT FROM AUTHOR]

: Copyright of Monaldi Archives for Chest Disease is the property of PAGEPress and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Bernardini, Federico, Nusca, Annunziata, Coletti, Federica, La Porta, Ylenia, Piscione, Mariagrazia, Vespasiano, Francesca, Mangiacapra, Fabio, Ricottini, Elisabetta, Melfi, Rosetta, Cavallari, Ilaria, Ussia, Gian Paolo, Grigioni, Francesco

المصدر: Pharmaceutics; Jul2023, Vol. 15 Issue 7, p1858, 25p

مصطلحات موضوعية: CARDIOVASCULAR diseases, TYPE 2 diabetes, PEOPLE with diabetes, VASCULAR smooth muscle, CARDIOVASCULAR system, GLYCEMIC control, CORONARY vasospasm

مستخلص: Atherosclerosis is the leading cause of death worldwide, especially in patients with type 2 diabetes mellitus (T2D). GLP-1 receptor agonists and DPP-4 inhibitors were demonstrated to play a markedly protective role for the cardiovascular system beyond their glycemic control. Several cardiovascular outcome trials (CVOT) reported the association between using these agents and a significant reduction in cardiovascular events in patients with T2D and a high cardiovascular risk profile. Moreover, recent evidence highlights a favorable benefit/risk profile in myocardial infarction and percutaneous coronary revascularization settings. These clinical effects result from their actions on multiple molecular mechanisms involving the immune system, platelets, and endothelial and vascular smooth muscle cells. This comprehensive review specifically concentrates on these cellular and molecular processes mediating the cardiovascular effects of incretins-like molecules, aiming to improve clinicians' knowledge and stimulate a more extensive use of these drugs in clinical practice as helpful cardiovascular preventive strategies. [ABSTRACT FROM AUTHOR]

: Copyright of Pharmaceutics is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Biccirè, Flavio Giuseppe, Gatto, Laura, La Porta, Ylenia, Pignatelli, Pasquale, Prati, Francesco, Pastori, Daniele

المصدر: Journal of Cardiovascular Development & Disease (JCDD); Jun2023, Vol. 10 Issue 6, p260, 16p

المؤلفون: Viscusi, Michele Mattia, La Porta, Ylenia, Migliaro, Giuseppe, Gargano, Gian Marco, Nusca, Annunziata, Gatto, Laura, Budassi, Simone, Paolucci, Luca, Mangiacapra, Fabio, Ricottini, Elisabetta, Melfi, Rosetta, Rinaldi, Raffaele, Prati, Francesco, Ussia, Gian Paolo, Grigioni, Francesco

المصدر: Photonics; Feb2023, Vol. 10 Issue 2, p158, 18p

مصطلحات موضوعية: OPTICAL coherence tomography, MYOCARDIAL infarction, ATHEROSCLEROTIC plaque, PERCUTANEOUS coronary intervention, DRUG therapy, CORONARY vasospasm, KNOWLEDGE gap theory

مستخلص: Since its ability to precisely characterized atherosclerotic plaque phenotypes, to tailor stent implantation, as well as to guide both complex percutaneous coronary interventions (PCI) and invasive diagnostic work-ups (e.g., spontaneous coronary dissections or myocardial infarction with non-obstructive arteries), the adoption of optical coherence tomography (OCT) was raised in the past decades in order to provide complementary information to the traditional angiography and to overcome its limitations. However, the impact of OCT on daily clinical practice is currently modest, firstly because of the lack of both standardized algorithms of PCI guidance and data from prospective clinical trials. Therefore, the aim of our narrative review is to provide a comprehensive overview of the basic OCT interpretation, to summarize the evidence supporting the OCT guidance procedures and applications, to discuss its current limitations, and to highlight the knowledge gaps that need to be filled with more robust evidence. [ABSTRACT FROM AUTHOR]

: Copyright of Photonics is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Cavallari, Ilaria, La Porta, Ylenia, Maddaloni, Ernesto, Appetecchia, Alessandro, D´onofrio, Luca, Grigioni, Francesco

المصدر: European Heart Journal Supplements ; volume 24, issue Supplement_K ; ISSN 1520-765X 1554-2815

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown to reduce renal and heart failure (HF) events in people with and without diabetes. Although their glycemic efficacy is dependent on kidney function, it remains unclear to what extent baseline kidney function influences the magnitude of SGLT2i cardiorenal effects. Methods We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials testing the effects of SGLT2i on renal and CV outcomes (PROSPERO registration number CRD42022325976). Efficacy outcomes, stratified by five estimated glomerular filtration rate (eGFR) categories, included progression of renal disease (as defined in each trial), a composite HF outcome (defined as CV death or hospitalization/urgent visit for HF), and all-cause mortality. Results Eleven trials testing five SGLT2i (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin and sotagliflozin) in 77,541 participants were included. The majority of participants (39.8%) had eGFR values between 60 and 90 ml/min/1.73m2, with only 1.3% having advanced kidney disease (eGFR between 20 and 30 ml/min/1.73m2). Overall, SGLT2i reduced the risk of renal disease progression by 41% (HR 0.59, 95%CI 0.54–0.65, p<0.001) and the risk of HF outcomes by 22% (HR 0.78, 95%CI 0.73–0.83, p<0.001). Meta-regression analyses showed a significant direct relationship between baseline eGFR and the magnitude of SGLT2i renal protection (p=0.040). The greatest relative risk reduction was in participants with eGFR values ≥90 ml/min/1.73m2 (HR 0.43, 95%CI 0.32–0.58) and the smallest was in those with an eGFR between 30 and 45 ml/min/1.73m2 (HR 0.64, 95%CI 0.55–0.76). Conversely, the HF outcome showed a non-significant trend to greater benefit in participants with lower eGFR categories (p=0.086). The greatest relative risk reduction was in those with an eGFR between 20 and 30 ml/min/1.73m2 (HR 0.68, 95%CI 0.48–0.96, p=0.026) and the smallest was in those with an eGFR ≥90ml/min/1.73m2 (HR 0.87, ...

الإتاحة: https://doi.org/10.1093/eurheartjsupp/suac121.461Test
https://academic.oup.com/eurheartjsupp/article-pdf/24/Supplement_K/suac121.461/47967358/suac121.461.pdfTest

المؤلفون: La Porta, Ylenia, Cavallari, Ilaria, Maddaloni, Ernesto, Appetecchia, Alessandro, Grigioni, Francesco

المصدر: European Heart Journal Supplements ; volume 24, issue Supplement_K ; ISSN 1520-765X 1554-2815

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Background Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated to reduce heart failure (HF) and renal outcomes irrespective of diabetes status. The cardiovascular efficacy and the mortality benefit of these agents in patients without HF and across the spectrum of left ventricular ejection fraction (EF) are a matter of debate. Methods This study-level meta-analysis included 11 controlled randomized trials and 76,520 patients randomized to a SGLT-2 inhibitor (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin and sotagliflozin) or placebo in different clinical settings including diabetes, HF with reduced or preserved EF and chronic kidney disease. Data were stratified by history of HF, HF with reduced EF (≤40%), mid-range EF (40-49%) and preserved EF (≥50%). The incidence of the following outcomes, when available, was evaluated: HF composite outcome, defined as cardiovascular death or hospitalization/urgent visit for HF, its individual components and all-cause mortality. An additional sensitivity analysis tested the efficacy of SGLT-2 inhibitors in patients with extremely reduced EF (≤30%). Results Overall, there were 22,653 patients with HF (33.8%) and 44,304 patients without HF (66.2%). In patients without history of HF, SGLT-2 inhibitors significantly reduced the risk of HF outcomes (HR 0.76, 95% CI 0.68-0.86) and all-cause mortality (HR 0.84, 95% CI 0.73-0.95). In patients with HF, a significant reduction in the composite of cardiovascular death and HF events was consistently observed in those with reduced EF (HR 0.71, 95% CI 0.65-0.78), mid-range EF (HR 0.68, 95% CI 0.57-0.81) and preserved EF (HR 0.78, 95% CI 0.69-0.89; Figure). There was a significant reduction in all-cause mortality also in patients with HF treated with SGLT-2 inhibitors (HR 0.87, 95% CI 0.80-0.95). Conclusions SGLT-2 inhibitors demonstrated cardiovascular and mortality benefits irrespective from history of HF and across the spectrum of left ventricular EF.

الإتاحة: https://doi.org/10.1093/eurheartjsupp/suac121.460Test
https://academic.oup.com/eurheartjsupp/article-pdf/24/Supplement_K/suac121.460/47967364/suac121.460.pdfTest

المؤلفون: Sammartini, Emanuele, Biccirè, Flavio Giuseppe, Debelak, Caterina, La Porta, Ylenia, Budassi, Simone, Varricchione, Giuseppe, Romagnoli, Enrico, Marco, Valeria, Boi, Alberto, Fineschi, Massimo, Fabbiocchi, Franco, Taglieri, Nevio, Calligaris, Giuseppe, Ozaki, Yukio, Arbustini, Eloisa, Alfonso, Fernando, Prati, Francesco

المصدر: European Heart Journal Supplements ; volume 24, issue Supplement_K ; ISSN 1520-765X 1554-2815

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine

الوصف: Background Several environmental and seasonal factors are thought to be crucial in the risk of acute coronary syndromes (ACS), including temperature, latitude, longitude, atmospheric air pressure, wind velocity and circadian period. However differences in coronary plaque composition according to season variation is still poorly understood. Purpose Our study aims to analyse the characteristics of non-culprit coronary plaques in patients undergoing optical coherence tomography evaluation (OCT) evaluation of the left anterior descending artery. Methods We included 1848 non-culprit coronary plaques from 1003 patients of the CLIMA registry. The season of OCT pullback acquisition was collected for each patient. Results Overall, median age was 66 years (56-74), with 24.6% of women and 53.4% of ACS. At patient-level analysis, patients admitted in summer were less frequently affected by hypertension (59.8% vs 69.4% in autumn, 68.5% in winter and 72% in spring; p=0.027) and chronic kidney disease (14.8% vs 15.9% in autumn, 10.3% in winter and 19.4% in spring; p=0.037) in. At lesion-level analysis, similar values of fibrous cap thickness, maximum lipid arc, length of plaques and presence of macrophages were observed (Table 1). Summer plaques had a smaller minimum lumen area than spring plaques (5.7±3.1 vs 5.1±239; p=0.044) and also a less frequent superficial macrophage infiltration (23% vs 36.1% in autumn, 30.5% in winter and 30.6% in spring; p=0.030) and presence of cholesterol crystals (16.7% vs 23.8% in autumn, 28.4% in winter and 22.1% in spring; p=0.037 than three other season). Table 1 Conclusions Coronary plaques during summer had less local sign of inflammation such superficial macrophage infiltration and cholesterol crystals. Further studies are needed to confirm these results and investigate clinical implications.

الإتاحة: https://doi.org/10.1093/eurheartjsupp/suac121.542Test
https://academic.oup.com/eurheartjsupp/article-pdf/24/Supplement_K/suac121.542/47965694/suac121.542.pdfTest

المؤلفون: LA PORTA, YLENIA

المساهمون: Bernardini, Nunzia, Testai, Lara

المصدر: http://etd.adm.unipi.it/theses/available/etd-01282021-120231Test/.

مصطلحات موضوعية: FARMACIA

الوصف: 1) Contesto e scopo I flavonoidi sono composti chimici naturali presenti nelle piante, noti per le loro proprietà salutistiche tra cui la loro azione antiossidante, antiinfiammatoria, cardioprotettrice oltre ad azioni benefiche nella prevenzione dell'obesità. Questo studio ha esaminato gli effetti del flavonoide apigenina sulle alterazioni infiammatorie del colon in un modello murino di obesità indotta dalla dieta. 2) Approccio sperimentale I topi maschi sono stati nutriti con dieta standard (SD) o dieta ricca di grassi (HFD). Gli animali sono stati trattati con apigenina (10 mg / Kg / giorno). Dopo 8 settimane sono state valutate l'infiltrazione di eosinofili e la deposizione di fibre collagene in campioni paraffinati di colon. 3) Risultati chiave Gli animali obesi HFD hanno mostrato un aumento di eosinofili e di fibre collagene deposte nello spessore della parete del colon rispetto ai controlli. L’infiammazione del colon correlata all'obesità è stata migliorata dall’apigenina, che ha ridotto l'infiltrazione di eosinofili e migliorato lo stato di fibrosi riducendo la presenza delle fibre collagene. 4) Conclusioni e implicazioni Nel nostro modello sperimentale di obesità da HFD l’apigenina riduce l'infiammazione enterica e normalizza lo stato fibrotico correlato ad una maggior presenza di fibre collagene.

وصف الملف: application/pdf

العلاقة: http://etd.adm.unipi.it/theses/available/etd-01282021-120231Test/

الإتاحة: http://etd.adm.unipi.it/theses/available/etd-01282021-120231Test/

المؤلفون: Vergallo, Rocco, La Porta, Ylenia, Porto, Italo, Annibali, Gianmarco, Galli, Mattia, D Amario, Domenico, Montone, Rocco A., Aurigemma, Cristina, Enrico Romagnoli, Leone, Antonio M., Niccoli, Giampaolo, Buffon, Antonino, Burzotta, Francesco, Trani, Carlo, Crea, Filippo

المصدر: Web of Science

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::388a4635fcf6875ead40e0f951b2db64Test
https://publons.com/wos-op/publon/31538898Test/